Surgery, Gastroenterology and Oncology
Vol. 20, No. 2, June 2015
Graft steatosis - where to stop?
Radu Zamfir, Vladislav Braşoveanu, Leonard David, Simona Dima, Florin Botea, Vasile Lungu, Tudor Stoian, Vlad Herlea, Nicolae Bacalbaşa, Sorin Ianceu, Florin Cristian Blăjuţ, Dana Tomescu, Irinel Popescu
ORIGINAL PAPER, June 2015
Article DOI: 10.21614/jtmr-20-2-33
The gap between the availability of livers from organ donors and the increased demand has led many centers to apply strategies to reduce this deficit. Splitting of cadaveric organs for use in 2 recipients; domino transplantation; and organs from living donors, nonâ€"heartbeating donors, and extended-criteria donors (ECDs) are all currently used in expanding the liver graft availability for orthotopic liver transplantation (OLT). Fatty changes in the donor liver are a risk factor for poor function after OLT, especially for primary non-function; however, the presence of steatosis, frequently present in livers from ECDs, does not exclude the use of these organs.
The aims were to study the steatosis as a cause of nonacceptance of a liver for transplantation after exploration by the donor surgical team.
All donor harvesting procedures performed by our unit from 2008 to 2014 were retrospectively studied. Donors were divided in those accepted and harvested and those discarded by the donor surgical team. Donor characteristics of accepted and used liver grafts were compared with those rejected due to steatosis. Five hundred sixty-one donor liver procurements were performed, out of which 60 (10.6%) demonstrated on liver biopsy macroscopic steatosis. Out of these 44 had mild steatosis (>30% but <60%) and 16 had severe steatosis (>60%). The main indication for biopsy was macroscopic doubt about the degree of steatosis. The main indication for discarding the liver was macrovesicular steatosis above 60%.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 2811


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.